Eton Pharmaceuticals, Inc. / Fundamentals
Income statement
- Net revenue
€49.92M - Cost of goods sold
€20.26M - Gross profit
€29.66M - SG&A expenses
€26.48M - R&D expenses
€3.87M - EBITDA
-€149.29K - D&A
€543.11K - EBIT
-€692.41K - Interest expenses
€1.30M - EBT
-€3.46M - Tax expenses
€86.66K - Net income
-€3.54M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€7.33M - Changes in working capital
-€921.49K - Operating cash flow
€10.50M - Capex
€5.37M - Other investing cash flow
-€32.71M - Net investing cash flow
-€31.11M - Total cash dividends paid
€0.00 - Issuance of common stock
-€151.01K - Debt repayment
€21.38M - Other financing cash flow
€7.43M - Net financing cash flow
€28.81M - Foreign exchange effects
€0.00 - Net change in cash
€6.59M - Cash at end of period
€21.78M - Free cash flow
€15.87M
Balance sheet
- Cash and cash equivalents
€21.78M - Cash and short-term investments
€21.78M - Total receivables
€12.40M - Inventory
€20.41M - Other current assets
€4.14M - Total current assets
€58.72M - Property, plant & equipment
€293.44K - Goodwill
€0.00 - Intangible assets
€28.21M - Long-term investments
€0.00 - Other non-current assets
€10.30K - Total non-current assets
€28.51M - Total assets
€87.24M - Accounts payable
€10.42M - Short-term debt
€2.40M - Other current liabilities
€20.02M - Total current liabilities
€33.12M - Long-term debt
€422.14K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€33.14M - Total non-current liabilities
€33.56M - Total liabilities
€66.68M - Common stock
€23.17K - Retained earnings
-€96.14M - Other equity
€0.00 - Total equity
€20.56M - Total liabilities and shareholders' equity
€87.24M
Company information
- Market capitalization
€320.47M - Employees
31 - Enterprise Value
€387.34M
Company ratios
- Gross margin
-
59.4% Much better than peer group: -4,652.1% - EBITDA margin
-
-0.3% Much better than peer group: -426,974.6% - EBIT margin
-
-1.4% Much better than peer group: -437,847.5% - EBT margin
-
-6.9% Much better than peer group: -429,341.1% - Net margin
-
-7.1% Much better than peer group: -411,888.2% - ROE
-
-17.2% Much better than peer group: -3,584.9% - ROA
-
-4.1% Much better than peer group: -47.8% - Asset turnover
-
57.2% Much worse than peer group: 362,373.9% - FCF margin
-
10.3% Much better than peer group: -342,345.9% - FCF yield
1.6% - Efficiency ratio
100.3% - Net sales per employee
-
€1.61M - Net income per employee
-
-€114.25K